For U.S. Healthcare Professionals Only
The first and only FDA-approved, NAM-modified cell therapy for patients with hematologic malignancies in need of an allogeneic hematopoietic cell transplant (allo-HCT).

Today's transplant landscape

Allo-HCT has curative potential, but no new donor sources have been introduced to overcome the challenges of availability, suitability, and deliverability

of an HLA-matched donor
of the donor source that minimizes the risk of post-transplant complications
of a donor source that sets consistent expectations for time to transplant
Appropriately HLA-matched donors are preferred for allo-HCT, but are not available for all patients
Matched related donors are only available for
30% of patients1
Matched unrelated donor availability varies greatly, and racially and ethnically diverse donors are underrepresented in donor registries2

Person icon
White patients of European descent
Person icon
Native American patients
Person icon
Hispanic or Latino patients
Person icon
Asian or Pacific Islander patients
Person icon
Black or African American patients
There is
no universal
standard of care
Alternative Donor Sources
Alternative donor sources icon
  • Haploidentical
  • Mismatched unrelated
  • Umbilical cord blood

Potential Risks3,4,5,6
Potential risks icon

Although alternative donor sources provide more options for patients, there may be additional risks associated, such as higher rates of graft-versus-host-disease (GvHD), infections, and non-relapse mortality (NRM).

Deliverability factors, including unrelated matched donor attrition and acquisition challenges may delay or prevent a patient from receiving an allo-HCT
Deliverability image Deliverability image

Start your patient’s Omisirge treatment journey today

Potential patients in need of an allogeneic transplant.
Potential patients in need of an allogeneic transplant.
Potential patients in need of an allogeneic transplant.
Potential patients in need of an allogeneic transplant.
Find an Omisirge treatment center near you.

Find an Omisirge treatment center near you
Omisirge is available at transplant centers nationwide. Find an Omisirge transplant center near your patient.
  1. Kindwall-Keller TL et al. Oncologist. 2017;22(9):1125-1134. doi:10.1634/theoncologist.2017-0009
  2. How does a patient’s ethnic background affect matching? Published March 10, 2023.
  3. Fabricius WA et al. Adv Hematol. 2016;2016:5726132. doi:10.1155/2016/5726132
  4. Pidala J et al. Blood. 2014;124(16):2596-2606. doi:
  5. Horwitz ME et al. J Clin Oncol. 2019;37(5):367-374. doi:10.1200/JCO.18.00053
  6. Giralt S et al. Cancer Treat Res. 2009;144:1-21. doi:10.1007/978-0-387-78580-6_1
  7. Anthias C et al. Biol Blood Marrow Transplant. 2020;26(3):593-599. doi:10.1016/j.bbmt.2019.10.012
  8. You’re a Potential Match. Published June 2015
  9. Ciurea SO et al. Blood Adv. 2018;2(17):2254-2261. doi:10.1182/bloodadvances.2018021899
  10. Eapen M et al. Lancet Haematol. 2017;4(7):e325-e333. doi:10.1016/S2352-3026(17)30104-7
  11. Eapen M et al. Lancet. 2007;369(9577):1947-1954. doi:10.1016/S0140-6736(07)60915-5
  12. Wang JC et al. Blood. 1997;89(11):3919-3924
  13. Goussetis E et al. Cytotherapy. 2003;5(6):500-508. doi:10.1080/14653240310003602
  14. DeZern AE et al. Blood Adv. 2021;5(5):1360-1368. doi:10.1182/bloodadvances.2020003922
  15. Omisirge (omidubicel-onlv). Prescribing Information. Gamida Cell Ltd.; 2023.